COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Norepinephrine for Spinal-induced Hypotension (NE in spianl)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03308708
Recruitment Status : Unknown
Verified October 2017 by AlRefaey Kandeel, Mansoura University.
Recruitment status was:  Not yet recruiting
First Posted : October 12, 2017
Last Update Posted : October 12, 2017
Information provided by (Responsible Party):
AlRefaey Kandeel, Mansoura University

Brief Summary:
Norepinephrine (NE) infusion is used prophylactically to counteract the vasodilator effect of spinal anesthesia. prophylactic use of NE infusion is expected to decrease bouts of hypotension, vomiting and increase patient satisfaction

Condition or disease Intervention/treatment Phase
Spinal Anesthesia Drug: Norepinephrine infusion Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Prophylactic Norepinephrine Infusion for Spinal-induced Hypotension
Estimated Study Start Date : November 1, 2017
Estimated Primary Completion Date : January 1, 2018
Estimated Study Completion Date : January 1, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: Control group
Experimental: NE group Drug: Norepinephrine infusion
Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state

Primary Outcome Measures :
  1. incidence of hypotension [ Time Frame: intraoperative ]
    intraoperative decrease of patient blood pressure by more than 20% from its basal reading

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients scheduled for elective surgery under spinal anesthesia

Exclusion Criteria:

  • ischemic heart disease uncontrolled hypertension

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03308708

Layout table for location information
Mansoura university
Al Manşūrah, Dkahleya, Egypt
Sponsors and Collaborators
Mansoura University
Layout table for additonal information
Responsible Party: AlRefaey Kandeel, Dr, Mansoura University Identifier: NCT03308708    
Other Study ID Numbers: NE_spinal
First Posted: October 12, 2017    Key Record Dates
Last Update Posted: October 12, 2017
Last Verified: October 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents